Kurma Partners

Avidicure is a biotechnology company developing a dual agonistic, multifunctional antibody modality engineered for targeted cancer immunotherapy. Its AVC-Boosters are designed to engage immune cells with high avidity and to localize activation within tumors, enabling potent anti-tumor activity as monotherapy while reducing off-target effects. The approach aims to advance oncology therapies by combining immune engagement with tumor-specific activation to support immune responses and potentially improve safety profiles.

Germitec is a healthcare company focused on the design and commercialization of ultraviolet light disinfection systems aimed at enhancing hospital hygiene. By specializing in high-level disinfection using UV-C technology, Germitec provides solutions for reprocessing non-lumen medical devices. The company's innovations are intended to simplify the responsibilities of healthcare professionals, improving safety and efficiency while effectively reducing the risk of cross-infection in clinical settings. Through its advanced disinfection systems, Germitec seeks to transform clinical practices and contribute to better healthcare outcomes.

Hopia is a scheduling solution specifically designed for healthcare institutions, focusing on the optimization of human and material resources. The platform centralizes the management of doctors' and nurses' schedules, employing constrained optimization and prediction algorithms to establish the most efficient organization for all stakeholders involved. By streamlining scheduling processes, Hopia aims to enhance operational efficiency, allowing healthcare personnel to allocate more time to patient care and improve overall service delivery in the healthcare sector.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

Omnidoc is a tele-expertise platform that enables healthcare professionals to exchange medical opinions efficiently. It is designed to facilitate phone-based medical verification for patients eligible for health insurance, allowing medical institutions and private physicians to obtain informal opinions. The platform strengthens the connections between primary care providers and specialized physicians while centralizing requests from correspondents. Omnidoc also assists clients in discovering and contacting relevant doctors and organizations, aimed at improving the quality and security of exchanged opinions. Additionally, it automates various administrative tasks, streamlining processes within healthcare communication.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs for orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution designed to treat T-cell leukemia in both pediatric and adult patients, as well as SH-105, another oncology drug. Shorla Pharma is dedicated to enhancing patient care and making a significant clinical impact through its innovative therapies.

Axithra specializes in therapeutic medication monitoring, specifically focusing on measuring beta-lactam antibiotic concentrations in blood. Its proprietary platform enables personalized treatments by accurately determining drug concentrations, optimizing patient care.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Ganymed Robotics is a medical device company that develops robotics technologies for orthopedic surgeons, including a therapeutic device designed to improve precision in knee replacement procedures. Founded in 2018 and based in Paris, the company aims to enhance surgical accuracy, reduce operating times, and improve patient outcomes by integrating robotics into the orthopedic workflow.

Charles helps men regain control over their daily health concerns by starting with their personal health.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Germitec is a healthcare company focused on the design and commercialization of ultraviolet light disinfection systems aimed at enhancing hospital hygiene. By specializing in high-level disinfection using UV-C technology, Germitec provides solutions for reprocessing non-lumen medical devices. The company's innovations are intended to simplify the responsibilities of healthcare professionals, improving safety and efficiency while effectively reducing the risk of cross-infection in clinical settings. Through its advanced disinfection systems, Germitec seeks to transform clinical practices and contribute to better healthcare outcomes.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

Founded in 2014, DAMAE Medical develops OCTAV, an innovative optical imaging technology that enables dermatologists to obtain high-resolution, non-invasive images of skin tissue similar to histology. This Paris-based medtech company aims to revolutionize skin cancer diagnosis and improve patient outcomes.

NaoX Technologies is a company focused on the prevention of neurological disorders through innovative technology. It develops wireless headphones equipped with integrated sensors that passively monitor brain vibrations to record electroencephalogram data in real time. This data is then aggregated and presented on a software dashboard for healthcare providers, facilitating better diagnosis and treatment for patients. The company's mission is to democratize access to neurological disorder prevention, aiming to enhance patient outcomes and support recovery from mental illness.

ARMGO Pharma is a biopharmaceutical company focused on developing small-molecule therapeutics to treat debilitating cardiac, skeletal muscle, and neurological disorders. It develops Rycals, calcium release channel stabilizers that act on the ryanodine receptor/calcium release channel on the sarcoplasmic/endoplasmic reticulum to address chronic heart failure, arrhythmias, muscle disorders, cognitive disorders, and related conditions. The company was founded in 2004 and is based in Tarrytown, New York, with an additional office in New York, New York.

Sunrise is a medical technology company focused on improving the diagnosis and management of sleep disorders, particularly sleep apnea, which affects nearly one billion people worldwide. The company has developed a 3-gram sensor that allows for rapid and accurate at-home diagnosis of sleep conditions, utilizing trigeminal drive analysis to detect respiratory events. This innovative device is clinically validated for use in both adults and children and provides a cost-effective alternative to traditional in-lab sleep studies. Users receive a single-use sensor delivered to their home, which connects easily to their phone for seamless operation. Following the test, Sunrise facilitates consultations with certified sleep doctors or connections to local sleep centers, addressing a critical need in a healthcare landscape where 80% of sleep apnea cases remain undiagnosed.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

Omnidoc is a tele-expertise platform that enables healthcare professionals to exchange medical opinions efficiently. It is designed to facilitate phone-based medical verification for patients eligible for health insurance, allowing medical institutions and private physicians to obtain informal opinions. The platform strengthens the connections between primary care providers and specialized physicians while centralizing requests from correspondents. Omnidoc also assists clients in discovering and contacting relevant doctors and organizations, aimed at improving the quality and security of exchanged opinions. Additionally, it automates various administrative tasks, streamlining processes within healthcare communication.

Arkhn is a company focused on healthcare data interoperability, addressing the challenges associated with accessing and managing healthcare data. It develops a specialized medical enterprise software that standardizes healthcare data, thereby enhancing patient care and supporting the work of medical teams. The platform aims to promote medical research and innovation while streamlining the management of healthcare centers. By facilitating access to accurate and comprehensive data, Arkhn enables healthcare establishments to better support patients and caregivers, ultimately accelerating advancements in medical research and improving overall healthcare delivery.

SmartCatch specializes in liquid biopsy technology aimed at enhancing cancer detection and treatment. The company has developed a minimally invasive method to extract circulating tumor cells, offering a series of products focused on the capture and isolation of these cells. This technology provides researchers and clinicians with valuable data that can significantly improve cancer patient outcomes. By empowering the medical community with advanced tools, SmartCatch contributes to the ongoing battle against cancer, facilitating better diagnostic and therapeutic approaches.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Argobio is a startup studio dedicated to cultivating innovative biotechnology solutions. It sources early-stage projects from leading European academic institutions focusing on rare diseases, neurological disorders, oncology, immunology, and platform technologies for therapeutic products.

Founded in 2009, Medlumics designs and manufactures catheter-based systems for treating supraventricular tachycardias. Utilizing optical coherence tomography technology, the company's products provide real-time, sectional information about tissue, enhancing procedural safety and efficacy.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Lucine is a company focused on improving patient health, primarily targeting pain management. It develops a mobile health application that offers a digital therapeutic solution designed to relieve pain within five minutes through analgesic neurostimulation. The application employs advanced algorithms to measure and analyze pain by utilizing facial, vocal, and postural recognition. This technology allows for personalized treatment, as it instantly adapts to each patient's specific needs. The application provides a variety of techniques to alleviate pain symptoms, including exercises, relaxation methods, art therapy, and meditation, empowering patients with chronic pain to manage their conditions effectively from home.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

FeetMe is a digital health company that develops a platform and connected footwear insoles for gait and movement analysis in-clinic and real-world settings. The technology combines pressure sensors, motion data, and learning algorithms to provide real-time gait and posture insights and digital biomarkers to support clinical research and improve care for patients with movement disorders and mobility constraints. These insights enable clinicians to monitor disease progression, tailor treatments, and optimize medication use by assessing mobility capacity and tracking changes over time.

Founded in 2014, Sensome develops innovative micro-sensor technology that transforms invasive vascular medical devices into connected healthcare devices. Its AI-powered sensors detect the composition of blockages during stroke treatment, initially focusing on neurovascular indications before expanding to peripheral vascular and cardiovascular applications.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Vivet Therapeutics SAS is a biotechnology company based in Paris, France, focused on the research, development, and commercialization of gene therapy treatments for inherited liver disorders and orphan diseases. Founded in 2016, the company utilizes a liver-tropic adeno-associated virus (AAV) to deliver therapeutic genes directly to hepatocytes, aiming to correct genetic disorders at the source. Vivet is particularly engaged in developing innovative solutions for conditions such as Wilson disease, Progressive Familial Intrahepatic Cholestasis (PFIC), and Citrullinemia Type I (CTLN1). To enhance its gene therapy approaches, Vivet collaborates with the Fundación para la Investigación Médica Aplicada at the Centro de Investigación Médica Aplicada, focusing on optimizing AAV vectors for targeted liver delivery and ensuring long-term expression of therapeutic genes.

Founded in 2015, ImCheck Therapeutics specializes in developing immunotherapeutics targeting members of the butyrophilin super-family for treating a range of autoimmune diseases, with a primary focus on immuno-oncology.

Founded in 2014, DAMAE Medical develops OCTAV, an innovative optical imaging technology that enables dermatologists to obtain high-resolution, non-invasive images of skin tissue similar to histology. This Paris-based medtech company aims to revolutionize skin cancer diagnosis and improve patient outcomes.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Xeltis is a clinical-stage medical device company developing bio-absorbable heart valves and blood vessels. Its RestoreX technology enables the body's natural healing system to create functional tissue within its devices, forming new valves or vessels over time. Headquartered in Zurich, Switzerland, with R&D and manufacturing facilities in Eindhoven, Netherlands, Xeltis aims to transform cardiovascular care.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Step Pharma, incorporated in 2014 and based in Paris, France, focuses on developing innovative drugs for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off of the Imagine Institute, the company emerged from research led by Pr. Alain Fischer on genetic immunodeficiencies. It operates as a joint venture with Sygnature Discovery, which provides integrated drug discovery resources, and Kurma Partners, a prominent investor in European healthcare and biotechnology. Step Pharma's proprietary small molecule therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that target cytidine triphosphate synthase 1. This approach allows for the selective modulation of immune cell populations, such as T and B cells, enhancing treatment efficacy and therapeutic outcomes for patients with autoimmune conditions.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

STAT-Diagnostica is a company dedicated to the development of near-patient testing products aimed at enhancing healthcare delivery. It specializes in creating point-of-care diagnostic devices designed for rapid turnaround applications and critical care environments. The company's flagship product, DiagCORE, is a portable multi-analyte instrument that supports both molecular and immunoassay testing across various clinical settings. By integrating multiple testing techniques into a single device, STAT-Diagnostica enables healthcare professionals to streamline patient care and improve diagnostic efficiency.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

ABM Pharma operates a nationwide network of community pharmacies to deliver home-based patient care. It partners with more than 5,000 pharmacies to provide home support, oxygen therapy, and related services, enabling patients to receive quality pharmacy care in their homes. Its technicians serve more than 30,000 patients, highlighting the company’s focus on expanding access to treatment through pharmacy networks.

Safe Orthopaedics SA, headquartered in Éragny-sur-Oise, France, is a medical technology company specializing in the development and marketing of sterile implants and single-use instruments for spinal fracture treatments. Founded in 2010, the company offers several product lines, including SteriSpine PS for spinal fractures and degenerative pathologies, SteriSpine VA for Kyphoplasty and Cement systems, SteriSpine LC for lumbar cage instrumentation, and SteriSpine CC for cervical cage instrumentation. These products are designed to enhance surgical outcomes and patient care in spinal surgery procedures both domestically and internationally.

Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.